The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

AIM: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Because of the large interpatient pharmacokinetic variability and established exposure‐response and exposure‐toxicity relationships in clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Westerdijk, Kim, Krens, Stefanie D., van der Graaf, Winette T.A., Mulder, Sasja F., van Herpen, Carla M.L., Smilde, Tineke, van Erp, Nielka P., Desar, Ingrid M.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Precision Medicine‐based Drug Treatment Individualization in Oncology–Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328649/
https://www.ncbi.nlm.nih.gov/pubmed/32358810
http://dx.doi.org/10.1111/bcp.14332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328649/
https://www.ncbi.nlm.nih.gov/pubmed/32358810
http://dx.doi.org/10.1111/bcp.14332

Ejemplares similares